Stockscreener 앱 받기
10.39
0.10%
-0.010
시간 외 거래:
10.26
-0.13
-1.25%
전일 마감가:
$10.40
열려 있는:
$10.4
하루 거래량:
1.84M
Relative Volume:
1.18
시가총액:
$3.26B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-15.27
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
+6.56%
1개월 성능:
+8.91%
6개월 성능:
+33.03%
1년 성능:
+21.52%
1일 변동 폭
$10.37
$10.68
1주일 범위
$9.66
$10.68
52주 변동 폭
$6.685
$10.68
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
10.39 | 3.27B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
146.42 | 64.92B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.60 | 45.60B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
8.95 | 39.54B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.01 | 23.00B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
453.07 | 20.06B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal Pharmaceuticals Hits New 52-Week High of $10.43 - Markets Mojo
Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market - MSN
Sentiment analysis tools applied to Amneal Pharmaceuticals Inc.2025 Price Targets & Weekly High Return Stock Opportunities - newser.com
What to expect from Amneal Pharmaceuticals Inc. in the next 30 daysQuarterly Market Review & Accurate Buy Signal Notifications - newser.com
Will breakout in Amneal Pharmaceuticals Inc. lead to full recoveryTrade Entry Report & Short-Term Trading Opportunity Alerts - newser.com
Measuring Amneal Pharmaceuticals Inc.’s beta against major indicesDay Trade & Capital Efficiency Focused Strategies - newser.com
Is Amneal Pharmaceuticals Inc. stock cheap compared to fundamentalsEarnings Growth Report & Safe Entry Zone Identification - newser.com
Chart based exit strategy for Amneal Pharmaceuticals Inc.Market Volume Summary & Smart Investment Allocation Insights - newser.com
Reversal indicators forming on Amneal Pharmaceuticals Inc. stockInsider Buying & Real-Time Market Trend Scan - newser.com
Will Amneal Pharmaceuticals Inc. price bounce be sustainable2025 Big Picture & AI Forecasted Stock Moves - newser.com
Using Python tools to backtest Amneal Pharmaceuticals Inc. strategiesQuarterly Earnings Summary & Stepwise Trade Execution Plans - newser.com
What analysts say about Amneal Pharmaceuticals Inc stockGap Up/Gap Down Analysis & Free Take Advantage Of Momentum - earlytimes.in
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - sharewise.com
3 Lesser-Known Healthcare Names With Major Upside in Store - sharewise.com
3 Lesser-Known Healthcare Names With Major Upside in Store - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at $10.36 By Investing.com - Investing.com Canada
Amneal Pharmaceuticals stock hits 52-week high at $10.36 - Investing.com
Technical analysis overview for Amneal Pharmaceuticals Inc. stock2025 Big Picture & Technical Buy Zone Confirmations - newser.com
Published on: 2025-10-01 09:03:57 - newser.com
Is it time to cut losses on Amneal Pharmaceuticals Inc.2025 Market Sentiment & Breakout Confirmation Alerts - newser.com
Applying Wyckoff theory to Amneal Pharmaceuticals Inc. stock2025 Momentum Check & Verified High Yield Trade Plans - newser.com
Amneal to Report Third Quarter 2025 Results on October 30, 2025 - The Manila Times
Global Biopharma Amneal Pharmaceuticals Schedules Q3 2025 Financial Results and Investor Conference - Stock Titan
Amneal Files Xolair Biosimilar In US ‘Earlier Than Expected’ - insights.citeline.com
Amneal Pharmaceuticals Inc Stock Analysis and ForecastDividend Stability Analysis & Explosive Profit Trading - earlytimes.in
How to read the order book for Amneal Pharmaceuticals Inc.2025 Institutional Moves & Fast Exit Strategy with Risk Control - newser.com
What drives Amneal Pharmaceuticals Inc stock priceRisk-Reward Ratio Analysis & Low Cost Stock Picks - Early Times
Amneal gets FDA nod for generic version of Risperdal Consta - MSN
Amneal submits biosimilar application for asthma drug Xolair - Investing.com India
Amneal submits biosimilar application for asthma drug Xolair By Investing.com - Investing.com South Africa
Amneal seeks FDA nod for generic targeting Xolair marketed by Roche and Novartis - Seeking Alpha
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab) - The Manila Times
Amneal announces BLA submission of biosimilar candidate to Xolair (omalizumab) - MarketScreener
$4.1 Billion Market Opportunity: Amneal's XOLAIR Biosimilar Filing Could Transform Asthma Treatment Access - Stock Titan
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.83%
9.21%
자본화:
|
볼륨(24시간):